SMARCD3 and pancreatic neoplasm: Further, FOXA1 was co-bound at 75% of common SMARCD3-dependent BAF binding sites (Fig. 4g); these results support a collaboration between the SMARCD3-containing BAF complex and FOXA1 in pancreatic cancer cells.